CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia

Update Il y a 4 ans
Reference: NCT00272584

Woman and Man

  • | Country :
  • Canada
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two parallel groups. There is also an open-label extension phase of 18 weeks. Both medications to be used in the study, clozapine and risperidone, are fully approved for the treatment of schizophrenia.


Inclusion criteria

  • Psychosis, Schizophrenia

Links